z-logo
open-access-imgOpen Access
Intravenous Administration of Azumolene to Reverse Malignant Hyperthermia in Swine
Author(s) -
Do Carmo P. L.,
ZapataSudo G.,
Trachez M. M.,
Antunes F.,
Guimarães S. E. F.,
Debom R.,
Rizzi M. D. R.,
Sudo R. T.
Publication year - 2010
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2010.0556.x
Subject(s) - malignant hyperthermia , medicine , dantrolene , halothane , anesthesia , acidosis , contracture , pco2 , respiratory acidosis , metabolic acidosis , muscle relaxant , caffeine , surgery , calcium
Background: The efficacy of intravenous (IV) administration of azumolene (Az), an analogue 30‐fold more soluble than dantrolene, on pigs susceptible to malignant hyperthermia (MH) is incompletely understood. Objective: To evaluate efficacy of Az on MH crisis in pigs. Animals: Eight normal (MHN) and 7 susceptible to MH (MHS) pigs (Landrace × Large White × Pietran). Methods: Prospective, laboratory trial. Hypermetabolic crisis was observed in MHS pigs, but not in MHN pigs, after a combined administration of inhaled halothane (1.5%) and IV injection of succinylcholine (SCh; 2.5 mg/kg). Susceptibility was confirmed using a caffeine and halothane contracture test. Az was administered 15 minutes after administration of SCh. Results: Respiratory acidosis (pH 7.16 ± 0.02; P co 2 , 46.2 ± 9.1 mmHg, HCO 3 , 22.5 ± 2.3 mmol/L), fever (38.2 ± 1.1°C), cardiac arrhythmias, and muscle contracture were observed in MHS pigs. MHS pigs (n = 5) treated with Az (2 mg/kg IV) survived the crisis with attenuation of signs (pH 7.30 ± 0.10; P co 2 , 36.3 ± 4.5 mmHg; HCO 3 , 22.9 ± 2.3 mmol/L) and recovery of normal muscle tone and cardiac rhythm. Conclusions and Clinical Importance: Az represents a possible substitute for dantrolene to reverse MH crisis in susceptible pigs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here